Susan Thomas

Susan Thomas


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2019 in Nature Reviews Materials
Verified
Journal Article
Closed access
PDF file
ASAlex Schudel
Alex Schudel
DFDavid M. Francis
David M. Francis
STSusan Thomas
Susan Thomas

30 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
DFDavid M. Francis
David M. Francis
MMMargaret P. Manspeaker
Margaret P. Manspeaker
ASAlex Schudel
Alex Schudel
LSLauren Sestito
Lauren Sestito
MOMeghan J. O’melia
Meghan J. O’melia
STSusan Thomas
Susan Thomas
Anticancer therapeutic effects can be improved by directing immune checkpoint blockade antibodies to tumor-draining lymph nodes.

18 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJihoon Kim
Jihoon Kim
DFDavid M. Francis
David M. Francis
LSLauren Sestito
Lauren Sestito
PAPaul A. Archer
Paul A. Archer
MMMargaret P. Manspeaker
Margaret P. Manspeaker
STSusan Thomas
Susan Thomas
Due to their autosynchronous roles in shaping the anti-tumor immune response, complex immune regulatory networks acting both locally within the tumor microenvironment as well as in its draining lymph nodes play critical roles in the cancer immunotherapy response. We describe herein a thermosensitive co-polymer hydrogel system formed from biocompatible polymers gelatin and Pluronic® F127 that are widely used in humans to enable the sustained release of a nitric oxide donor and antibody blocking immune checkpoint cytotoxic T-lymphocyte-associated protein-4 for efficient and durable anti-tumor immunotherapy. By virtue of its unique gel formation and degradation properties that sustain drug retention at the tumor tissue site for triggered release by the tumor microenvironment and formation of in situ micelles optimum in size for lymphatic uptake, this rationally designed thermosensitive hydrogel facilitates modulation of two orthogonal immune signaling networks relevant to the regulation of the anti-tumor immune response to improve local and abscopal effects of cancer immunotherapy.

1 June 2020 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
ASAlex Schudel
Alex Schudel
ACAsheley Poole Chapman
Asheley Poole Chapman
MYMei-Kwan Yau
Mei-Kwan Yau
CHCody James Higginson
Cody James Higginson
DFDavid Mark Francis
David Mark Francis
STSusan Thomas
Susan Thomas
Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex and paracortex is difficult. Here, we describe a delivery system to overcome lymphatic and intra-lymph node transport barriers by combining nanoparticles that are rapidly conveyed to draining lymph nodes after administration in peripheral tissues with programmable degradable linkers. This platform enables the controlled release of intra-lymph-mobile small-molecular cargo, which can reach vastly more immune cells throughout the lymph node than either the particles or free compounds alone. The release rate can be programmed, allowing access to different lymph node structures and therefore specific lymphocyte subpopulations. We are thus able to alter the subtypes of drugged lymph node cells to improve immunotherapeutic effects.

1 February 2015 in Current Opinion in Chemical Engineering
Verified
Journal Article
Closed access
STSusan Thomas
Susan Thomas
ASAlex Schudel
Alex Schudel

11 July 2016 in Annual Review of Biomedical Engineering
Verified
Journal Article
Closed access
STSusan Thomas
Susan Thomas
NRNathan A. Rohner
Nathan A. Rohner
EEErin E. Edwards
Erin E. Edwards
Adaptive immune response consists of many highly regulated, multistep cascades that protect against infection while preserving the health of autologous tissue. The proper initiation, maintenance, and resolution of such responses require the precise coordination of molecular and cellular signaling over multiple time and length scales orchestrated by lymphatic transport. In order to investigate these functions and manipulate them for therapy, a comprehensive understanding of how lymphatics influence immune physiology is needed. This review presents the current mechanistic understanding of the role of the lymphatic vasculature in regulating biomolecule and cellular transport from the interstitium, peripheral tissue immune surveillance, the lymph node stroma and microvasculature, and circulating lymphocyte homing to lymph nodes. This review also discusses the ramifications of lymphatic transport in immunity as well as tolerance and concludes with examples of how lymphatic-mediated targeting of lymph nodes has been exploited for immunotherapy applications.